Cryptocurrency
Hoskinson warns CLARITY Act risks crypto growth
Cardano founder Charles Hoskinson warned the proposed US Digital Asset Market CLARITY Act could take more than a decade to implement and be vulnerable to political shifts.
Mahathir Bayena
Crypto JournalistCrypto journalist for Grafa, with nearly 10 years of experience covering blockchain, Web3, and NFT gaming trends. MBA & Economics grad.
Contact
Contact editorial teamArticles by Mahathir Bayena
Star exits Queen's Wharf ownership amid recapitalisation
Star Entertainment Group (ASX:SGR) has finalised its exit from the Queen’s Wharf Brisbane ownership consortium.
Red Sky Energy raises $5.2M for Innamincka drilling
Red Sky Energy (ASX:ROG) announced a strategic capital raising initiative to secure up to $5.2 million in funding.
Economy
Fair Work Commission abolishes junior rates for young adults
Australia's Fair Work Commission has moved to abolish junior pay rates for workers aged 18 to 20 in the retail, fast-food, and pharmacy sectors.
Metallium secures 10-year offtake deal with Indium
Metallium (ASX:MTM) executed a binding 10-year off-take agreement with New York-based Indium.
Energy
Beach Energy CEO slams 'naive' gas reservation plan
Beach Energy (ASX:BPT) CEO Brett Woods has launched a pointed critique of the Albanese government’s proposed domestic gas reservation scheme.
Hastings acquires Thai plant for near-term production
Hastings Technology Metals (ASX:HAS) announced the acquisition of a fully permitted hydrometallurgical processing facility in Kabin Buri, Thailand.
RBA bans card surcharges to save $1.6B
The Reserve Bank of Australia announced a landmark ban on card surcharging effective Oct. 1.
Novo Nordisk unveils Wegovy subscription model to combat patient attrition and pricing war
Novo Nordisk (NYSE:NVO) announced a strategic shift in its commercial approach on Tuesday, March 31, 2026, launching a multi-month subscription program for its flagship obesity medication, Wegovy.
Health
Cadrenal Therapeutics progresses toward Phase 3 following positive FDA end-of-Phase 2 meeting
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.